Monthly
US$200
Billed every month
环硅酸锆钠散
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 4 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders5View records ↓
Under-review filings12View records ↓
This year’s generic filers3View records ↓
NHSA approval numbers11View records ↓
API companies with A status5View records ↓
Chemical-drug catalogue
Loaded records: 5 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 5 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 石家庄科仁医药科技有限公司 | 河北仁合益康药业有限公司 | 国药准字H20265643 | 2026/08/18 | 10g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 石家庄科仁医药科技有限公司 | 河北仁合益康药业有限公司 | 国药准字H20265644 | 2026/08/18 | 5g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南先声药业有限公司 | 海南先声药业有限公司 | 国药准字H20264562 | 2026/05/27 | 5g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 海南先声药业有限公司 | 海南先声药业有限公司 | 国药准字H20264561 | 2026/05/27 | 10g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 阿斯利康制药有限公司 | 阿斯利康制药有限公司 | 国药准字H20264270 | 2026/05/07 | 10g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 阿斯利康制药有限公司 | 阿斯利康制药有限公司 | 国药准字H20264271 | 2026/05/07 | 5g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南明瑞制药股份有限公司 | 湖南明瑞制药股份有限公司 | 国药准字H20263678 | 2026/03/17 | 5g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南明瑞制药股份有限公司 | 湖南明瑞制药股份有限公司 | 国药准字H20263679 | 2026/03/17 | 10g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 时森海（杭州）医药科技有限公司 | 浙江皓格药业有限公司 | 国药准字H20255115 | 2025/08/19 | 5g | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 11 distinct approval numbers and 6 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 阿斯利康制药有限公司 | 国药准字H20264271 | 5g | Category B (乙) | XV03AEH113P001010101359 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20263678 | 5g | Category B (乙) | XV03AEH113P001010105001 | NHSA |
| 海南先声药业有限公司 | 国药准字H20264561 | 10g | Category B (乙) | XV03AEH113P001010105849 | NHSA |
| AstraZeneca AB | 国药准字HJ20190072 | 5g | Category B (乙) | XV03AEH113P001010179096 | NHSA |
| 石家庄科仁医药科技有限公司 | 国药准字H20265643 | 10g | Category B (乙) | XV03AEH113P001010183837 | NHSA |
| 时森海(杭州)医药科技有限公司 | 国药准字H20255115 | 5g | Category B (乙) | XV03AEH113P001010184858 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20263678 | 5g | Category B (乙) | XV03AEH113P001010205001 | NHSA |
| 石家庄科仁医药科技有限公司 | 国药准字H20265643 | 10g | Category B (乙) | XV03AEH113P001010283837 | NHSA |
| 时森海(杭州)医药科技有限公司 | 国药准字H20255115 | 5g | Category B (乙) | XV03AEH113P001010284858 | NHSA |
| AstraZeneca AB | 国药准字HJ20190072 | 5g | Category B (乙) | XV03AEH113P001010379096 | NHSA |
| 石家庄科仁医药科技有限公司 | 国药准字H20265643 | 10g | Category B (乙) | XV03AEH113P001010383837 | NHSA |
| 时森海(杭州)医药科技有限公司 | 国药准字H20255115 | 5g | Category B (乙) | XV03AEH113P001010384858 | NHSA |
| 石家庄科仁医药科技有限公司 | 国药准字H20265643 | 10g | Category B (乙) | XV03AEH113P001010483837 | NHSA |
| 时森海(杭州)医药科技有限公司 | 国药准字H20255115 | 5g | Category B (乙) | XV03AEH113P001010484858 | NHSA |
| 时森海(杭州)医药科技有限公司 | 国药准字H20255115 | 5g | Category B (乙) | XV03AEH113P001010584858 | NHSA |
| 湖南明瑞制药股份有限公司 | 国药准字H20263679 | 10g | Category B (乙) | XV03AEH113P001020105001 | NHSA |
| 海南先声药业有限公司 | 国药准字H20264562 | 5g | Category B (乙) | XV03AEH113P001020105849 | NHSA |
| 石家庄科仁医药科技有限公司 | 国药准字H20265644 | 5g | Category B (乙) | XV03AEH113P001020183837 | NHSA |
| AstraZeneca AB | 国药准字HJ20190073 | 10g | Category B (乙) | XV03AEH113P001020279096 | NHSA |
| 石家庄科仁医药科技有限公司 | 国药准字H20265644 | 5g | Category B (乙) | XV03AEH113P001020283837 | NHSA |
| AstraZeneca AB | 国药准字HJ20190073 | 10g | Category B (乙) | XV03AEH113P001020379096 | NHSA |
| 石家庄科仁医药科技有限公司 | 国药准字H20265644 | 5g | Category B (乙) | XV03AEH113P001020383837 | NHSA |
| 石家庄科仁医药科技有限公司 | 国药准字H20265644 | 5g | Category B (乙) | XV03AEH113P001020483837 | NHSA |
| 阿斯利康制药有限公司 | 国药准字H20264270 | 10g | Category B (乙) | XV03AEH113P001020101359 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 12 filings and 6 distinct first applicants.
Generic 8 · Supplement 4
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 南京正大天晴制药有限公司 | CYHS2601462 | Generic | 2026/06/22 | Not stated by source | CDE |
| 南京正大天晴制药有限公司 | CYHS2601461 | Generic | 2026/06/22 | Not stated by source | CDE |
| 宁波美诺华天康药业有限公司 | CYHS2602582 | Generic | 2026/10/21 | Not stated by source | CDE |
| 宁波美诺华天康药业有限公司 | CYHS2602581 | Generic | 2026/10/21 | Not stated by source | CDE |
| 阿斯利康制药有限公司 | CYHB2601884 | Supplement | 2026/10/13 | Not stated by source | CDE |
| 阿斯利康制药有限公司 | CYHB2601883 | Supplement | 2026/10/13 | Not stated by source | CDE |
| 杭州仟源保灵药业有限公司 | CYHS2600593 | Generic | 2026/03/02 | Not stated by source | CDE |
| 杭州仟源保灵药业有限公司 | CYHS2600592 | Generic | 2026/03/02 | Not stated by source | CDE |
| AstraZeneca AB;AndersonBrecon Inc.;AstraZeneca Pharmaceuticals LP | JYHB2600082 | Supplement | 2026/02/05 | Not stated by source | CDE |
| AstraZeneca AB;AndersonBrecon Inc.;AstraZeneca Pharmaceuticals LP | JYHB2600081 | Supplement | 2026/02/05 | Not stated by source | CDE |
| 四川国为制药有限公司 | CYHS2503567 | Generic | 2025/09/29 | Not stated by source | CDE |
| 四川国为制药有限公司 | CYHS2503566 | Generic | 2025/09/29 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 6 filings and 3 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 南京正大天晴制药有限公司 | CYHS2601462 | Generic | 2026/06/22 | Not stated by source | CDE |
| 南京正大天晴制药有限公司 | CYHS2601461 | Generic | 2026/06/22 | Not stated by source | CDE |
| 宁波美诺华天康药业有限公司 | CYHS2602582 | Generic | 2026/10/21 | Not stated by source | CDE |
| 宁波美诺华天康药业有限公司 | CYHS2602581 | Generic | 2026/10/21 | Not stated by source | CDE |
| 杭州仟源保灵药业有限公司 | CYHS2600593 | Generic | 2026/03/02 | Not stated by source | CDE |
| 杭州仟源保灵药业有限公司 | CYHS2600592 | Generic | 2026/03/02 | Not stated by source | CDE |
API registrations
Non-component matches: 5 companies with A status and 3 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 环硅酸锆钠 | 福建南方制药股份有限公司 | Y20260000426 | I | Exact ingredient | 2026/06/10 | CDE |
| 环硅酸锆钠 | 江苏嘉逸医药有限公司 | Y20250001434 | I | Exact ingredient | 2026/02/13 | CDE |
| 环硅酸锆钠 | 四川国为制药有限公司 | Y20250000749 | I | Exact ingredient | 2025/08/05 | CDE |
| 环硅酸锆钠 | 河北安健成益医药科技有限公司 | Y20250000023 | A | Exact ingredient | 2026/08/24 | CDE |
| 环硅酸锆钠 | 江苏先盛生物医药有限公司 | Y20240001337 | A | Exact ingredient | 2026/07/24 | CDE |
| 环硅酸锆钠 | 湖南明瑞制药股份有限公司 | Y20240000919 | A | Exact ingredient | 2026/09/11 | CDE |
| 环硅酸锆钠 | AstraZeneca AB | Y20230000568 | A | Exact ingredient | 2025/07/22 | CDE |
| 环硅酸锆钠 | 浙江皓格药业有限公司 | Y20230000476 | A | Exact ingredient | 2026/07/03 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/10/21Accepted
-
2026/10/21Accepted
-
2026/10/13Accepted
-
2026/10/13Accepted
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to this drug
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy